HLB Life Science Co. Ltd (067630) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.016x

Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has a cash flow conversion efficiency ratio of -0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.30 Billion ≈ $-2.92 Million USD) by net assets (₩277.26 Billion ≈ $187.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

HLB Life Science Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how HLB Life Science Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 067630 total debt and obligations for a breakdown of total debt and financial obligations.

HLB Life Science Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HLB Life Science Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Zig Sheng Industrial Co Ltd TW:1455	0.090x
Onde SA WAR:OND	0.101x
Luda Technology Group Limited NYSE MKT:LUD	0.262x
MCH Group AG SW:MCHN	0.108x
Thessaloniki Water Supply & Sewerage Co S.A AT:EYAPS	0.000x
WiSoL CO.LTD KQ:122990	0.024x
YFC-BonEagle Electric Co Ltd TWO:6220	0.174x
Here Group Limited NASDAQ:HERE	0.029x

Annual Cash Flow Conversion Efficiency for HLB Life Science Co. Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of HLB Life Science Co. Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of HLB Life Science Co. Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩398.83 Billion ≈ $270.28 Million	₩-32.01 Billion ≈ $-21.69 Million	-0.080x	-85.25%
2023-12-31	₩231.21 Billion ≈ $156.69 Million	₩-10.02 Billion ≈ $-6.79 Million	-0.043x	+65.81%
2022-12-31	₩234.72 Billion ≈ $159.07 Million	₩-29.74 Billion ≈ $-20.16 Million	-0.127x	-121.50%
2021-12-31	₩246.19 Billion ≈ $166.84 Million	₩-14.08 Billion ≈ $-9.54 Million	-0.057x	-917.36%
2020-12-31	₩287.18 Billion ≈ $194.62 Million	₩2.01 Billion ≈ $1.36 Million	0.007x	+118.86%
2019-12-31	₩333.82 Billion ≈ $226.23 Million	₩-12.39 Billion ≈ $-8.39 Million	-0.037x	+26.58%
2018-12-31	₩219.09 Billion ≈ $148.47 Million	₩-11.07 Billion ≈ $-7.50 Million	-0.051x	-783.95%
2017-12-31	₩52.83 Billion ≈ $35.80 Million	₩-302.04 Million ≈ $-204.69K	-0.006x	+93.04%
2016-12-31	₩27.68 Billion ≈ $18.76 Million	₩-2.27 Billion ≈ $-1.54 Million	-0.082x	+51.02%
2015-12-31	₩25.90 Billion ≈ $17.55 Million	₩-4.34 Billion ≈ $-2.94 Million	-0.168x	-121.60%
2014-12-31	₩13.44 Billion ≈ $9.11 Million	₩10.43 Billion ≈ $7.07 Million	0.776x	+190.44%
2013-12-31	₩11.03 Billion ≈ $7.48 Million	₩2.95 Billion ≈ $2.00 Million	0.267x	-86.53%
2012-12-31	₩7.04 Billion ≈ $4.77 Million	₩13.97 Billion ≈ $9.47 Million	1.984x	--

About HLB Life Science Co. Ltd

KQ:067630 Korea Pharmaceuticals

Market Cap

$136.50 Million

₩201.42 Billion KRW

Market Cap Rank

#17990 Global

#881 in Korea

Share Price

₩4300.00

Change (1 day)

+0.70%

52-Week Range

₩3235.00 - ₩6630.00

All Time High

₩23674.87